PRMT1 protein expression was significantly higher in GC samples than in NATs from human patients (n = 30, P = 0.010), with 70% of samples showing an increased PRMT1 level, while c-Fos was expressed in tumor tissue in approximately 73.3% of patients. This evidence concerns the gene FOS and neoplasm.